Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.28 EUR 4.11% Market Closed
Market Cap: 106.3m EUR
Have any thoughts about
Heidelberg Pharma AG?
Write Note

Intrinsic Value

HPHA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one HPHA stock under the Base Case scenario is 2.65 EUR. Compared to the current market price of 2.28 EUR, Heidelberg Pharma AG is Undervalued by 14%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HPHA Intrinsic Value
2.65 EUR
Undervaluation 14%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Heidelberg Pharma AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for HPHA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about HPHA?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Heidelberg Pharma AG

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Heidelberg Pharma AG

Provide an overview of the primary business activities
of Heidelberg Pharma AG.

What unique competitive advantages
does Heidelberg Pharma AG hold over its rivals?

What risks and challenges
does Heidelberg Pharma AG face in the near future?

Has there been any significant insider trading activity
in Heidelberg Pharma AG recently?

Summarize the latest earnings call
of Heidelberg Pharma AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Heidelberg Pharma AG.

Provide P/S
for Heidelberg Pharma AG.

Provide P/E
for Heidelberg Pharma AG.

Provide P/OCF
for Heidelberg Pharma AG.

Provide P/FCFE
for Heidelberg Pharma AG.

Provide P/B
for Heidelberg Pharma AG.

Provide EV/S
for Heidelberg Pharma AG.

Provide EV/GP
for Heidelberg Pharma AG.

Provide EV/EBITDA
for Heidelberg Pharma AG.

Provide EV/EBIT
for Heidelberg Pharma AG.

Provide EV/OCF
for Heidelberg Pharma AG.

Provide EV/FCFF
for Heidelberg Pharma AG.

Provide EV/IC
for Heidelberg Pharma AG.

Show me price targets
for Heidelberg Pharma AG made by professional analysts.

What are the Revenue projections
for Heidelberg Pharma AG?

How accurate were the past Revenue estimates
for Heidelberg Pharma AG?

What are the Net Income projections
for Heidelberg Pharma AG?

How accurate were the past Net Income estimates
for Heidelberg Pharma AG?

What are the EPS projections
for Heidelberg Pharma AG?

How accurate were the past EPS estimates
for Heidelberg Pharma AG?

What are the EBIT projections
for Heidelberg Pharma AG?

How accurate were the past EBIT estimates
for Heidelberg Pharma AG?

Compare the revenue forecasts
for Heidelberg Pharma AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Heidelberg Pharma AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Heidelberg Pharma AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Heidelberg Pharma AG compared to its peers.

Compare the P/E ratios
of Heidelberg Pharma AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Heidelberg Pharma AG with its peers.

Analyze the financial leverage
of Heidelberg Pharma AG compared to its main competitors.

Show all profitability ratios
for Heidelberg Pharma AG.

Provide ROE
for Heidelberg Pharma AG.

Provide ROA
for Heidelberg Pharma AG.

Provide ROIC
for Heidelberg Pharma AG.

Provide ROCE
for Heidelberg Pharma AG.

Provide Gross Margin
for Heidelberg Pharma AG.

Provide Operating Margin
for Heidelberg Pharma AG.

Provide Net Margin
for Heidelberg Pharma AG.

Provide FCF Margin
for Heidelberg Pharma AG.

Show all solvency ratios
for Heidelberg Pharma AG.

Provide D/E Ratio
for Heidelberg Pharma AG.

Provide D/A Ratio
for Heidelberg Pharma AG.

Provide Interest Coverage Ratio
for Heidelberg Pharma AG.

Provide Altman Z-Score Ratio
for Heidelberg Pharma AG.

Provide Quick Ratio
for Heidelberg Pharma AG.

Provide Current Ratio
for Heidelberg Pharma AG.

Provide Cash Ratio
for Heidelberg Pharma AG.

What is the historical Revenue growth
over the last 5 years for Heidelberg Pharma AG?

What is the historical Net Income growth
over the last 5 years for Heidelberg Pharma AG?

What is the current Free Cash Flow
of Heidelberg Pharma AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Heidelberg Pharma AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Heidelberg Pharma AG

Current Assets 52.4m
Cash & Short-Term Investments 36.6m
Receivables 3.2m
Other Current Assets 12.7m
Non-Current Assets 13.4m
PP&E 3.5m
Intangibles 8.9m
Other Non-Current Assets 975.3k
Current Liabilities 8.7m
Accounts Payable 5.2m
Other Current Liabilities 3.5m
Non-Current Liabilities 21.2m
Long-Term Debt 21.2m
Efficiency

Earnings Waterfall
Heidelberg Pharma AG

Revenue
8.5m EUR
Cost of Revenue
-1.7m EUR
Gross Profit
6.8m EUR
Operating Expenses
-27.2m EUR
Operating Income
-20.4m EUR
Other Expenses
1.6m EUR
Net Income
-18.8m EUR

Free Cash Flow Analysis
Heidelberg Pharma AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

HPHA Profitability Score
Profitability Due Diligence

Heidelberg Pharma AG's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 3-Year Average ROE
ROE is Increasing
ROIC is Increasing
39/100
Profitability
Score

Heidelberg Pharma AG's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

HPHA Solvency Score
Solvency Due Diligence

Heidelberg Pharma AG's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Negative Net Debt
44/100
Solvency
Score

Heidelberg Pharma AG's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HPHA Price Targets Summary
Heidelberg Pharma AG

Wall Street analysts forecast HPHA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HPHA is 11.53 EUR with a low forecast of 11.41 EUR and a high forecast of 11.87 EUR.

Lowest
Price Target
11.41 EUR
401% Upside
Average
Price Target
11.53 EUR
406% Upside
Highest
Price Target
11.87 EUR
420% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for HPHA?

Click here to dive deeper.

Dividends

Heidelberg Pharma AG
does not pay dividends
Shareholder Yield

Current shareholder yield for HPHA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

HPHA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Heidelberg Pharma AG Logo
Heidelberg Pharma AG

Country

Germany

Industry

Biotechnology

Market Cap

106.3m EUR

Dividend Yield

0%

Description

Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.

Contact

BADEN-WUERTTEMBERG
Ladenburg
Schriesheimer Strasse 101
+49620310090.0
www.heidelberg-pharma.com

IPO

2006-11-13

Employees

89

Officers

CEO & Spokesman of the Executive Board
Prof. Andreas Pahl
Chief Financial Officer
Mr. Walter Miller
Chief Operating Officer
Dr. Jorg Kemkowski
Director Corporate Communication
Sylvia Wimmer
Chief Medical Officer
Dr. Andras Strassz
Chief Business Officer
Dr. George Octavian Badescu

See Also

Discover More
What is the Intrinsic Value of one HPHA stock?

The intrinsic value of one HPHA stock under the Base Case scenario is 2.65 EUR.

Is HPHA stock undervalued or overvalued?

Compared to the current market price of 2.28 EUR, Heidelberg Pharma AG is Undervalued by 14%.

Back to Top